FDA delays decision on Moderna’s COVID-19 vaccine for adolescents

The U.S. Food and Drug Administration told Moderna that it must further investigate the risk of myocarditis after vaccination before it can authorize the company’s COVID-19 vaccine for adolescents. The timeline for authorization has been bumped back until early 2022.

Leave a Reply